PP-137 \{ATRIAL\} \{FIBRILLATION\} \{FOLLOWING\} \{ELECTIVE\} \{CORONARY\} \{BYPASS\} \{SURGERY\} \{WITHOUT\} \{CARDIOPULMONARY\} \{BYPASS\} \{IN\} \{MALE\} \{PATIENTS\} \{WITH\} \{SEVERE\} \{LV\} DYSFUNCTION: \{WHAT\} \{IS\} \{EXACT\} \{PREDICTING\} \{ROLE\}...
et al.What nuclear cardiology can learn from nuclear oncology.J Nucl Cardiol10, 324–328 (2003). https://doi.org/10.1016/S1071-3581(03)00521-X https://doi.org/10.1016/S1071-3581(03)00521-X
We hypothesized that reductions in left atrial volume (LAV) with a cardiac resynchronization therapy–defibrillator (CRT-D) would translate into a subseque... A Brenyo,MS Link,A Barsheshet,... - 《Journal of the American College of Cardiology》 被引量: 282发表: 2011年 A simplified bivent...
BC Staff - 《British Journal of Cardiology》 被引量: 0发表: 2010年 [Late cerebrovascular complications of cardiac transplantation] The occurrence of stroke after the post-operative period of cardiac transplantation is a rare event, and the role of the cardiac transplant in these patien... B, ...
Heart Failure (HF) is one of the leading problems in cardiology practice today. Acute decompensated heart failure (ADHF) is a significant caus
A 57-year-old man with nonischemic dilated cardiomyopathy, New York Heart Association class III heart failure, and a narrow QRS complex was enrolled in an ongoing research study to assess the impact of cardiac resynchronization therapy (CRT) in patients with echocardiographically detected dyssyn- ...
Jeffrey Soble, a practicing cardiologist at Rush University Medical Group’s Cardiology Intensive Care Unit, and CEO of Ascend Cardiovascular, he addresses the practical realities of artificial intelligence in echocardiology, the primary challenges echocardiographers face that AI support, and where he ...
Stem cell therapy has been developing for the last 40 years, and it has shown results in the treatment of different diseases, from neurological to heart and autoimmune pathologies. At the same time, in the news or on the internet, cell therapy is often promoted with alerts that it has adve...
Heart failure after myocardial infarction is the leading cause of mortality and morbidity worldwide. Existing medical and interventional therapies can only reduce the loss of cardiomyocytes during myocardial infarction but are unable to replenish the per
Heart failure after myocardial infarction is the leading cause of mortality and morbidity worldwide. Existing medical and interventional therapies can only reduce the loss of cardiomyocytes during myocardial infarction but are unable to replenish the per